LTC004 + toripalimab

LTC004 + toripalimab is an investigational immunotherapy combination being evaluated for the treatment of advanced solid tumors resistant to first-line immunotherapy. Toripalimab is a humanized IgG4 monoclonal antibody that targets PD-1 (programmed death protein-1), functioning as an immune checkpoint inhibitor. It works by blocking the interaction between PD-1 and its ligands, enhancing T-cell responses against cancer cells. The specific mechanism of LTC004 is not clearly described in the available information. In clinical trials, the combination is administered intravenously with LTC004 at 45μg/kg and toripalimab at 240mg every three weeks.